Treatment of @entity1 with @entity6011 . Experience at the XXXX 's Hospital of Philadelphia, 1958-1984.

@entity1 @entity632 @entity66 @entity242 @entity41 @entity5 @entity786 @entity4316 @entity6011 @entity1891 @entity4786
Twenty-four @entity1 aged 3 months to 18 years (median, 12 years) were treated for @entity6011 at the @entity1 's Hospital of Philadelphia Cancer Research Center from 1958 through 1984. Sixteen @entity1 had @entity4786 ( @entity4786 ). The @entity5 arose in an extremity or in the trunk (15 @entity1 ), the retroperitoneum-pelvis (6), or other sites (3). Twelve @entity1 underwent grossly complete excision of localized @entity242 ; of them, five had no known @entity41 and seven had proven microscopic @entity66 . Ten of the remaining 12 @entity1 had grossly visible, residual localized disease, and two had lung metastases. After operation, nine were treated on a protocol with local radiation therapy (4000-6000 rad) plus @entity1891 , @entity4316 , and @entity786 with or without @entity632 ( @entity632 ). The other 15 were treated variably. At 3 years, the proportion of @entity5 -free survivors was 9 of 24 (37.5%). The significant favorable factors were the initial surgical removal of all gross @entity5 (9 of 12 with @entity5 excision were @entity5 -free survivors at 3 years compared to none of 12 with gross residual @entity242 ; P less than 0.01), and a @entity5 mitotic rate under one per high-power field. No significant correlation was found between @entity5 -free survival expectancy and age, race, sex, the presence of @entity4786 , the site and size of the @entity5 , or use of the chemoradiotherapy regimen. More effective treatment programs are needed for @entity1 with @entity6011 , especially for those with unresectable @entity5 .
